Patents | Published:

The 'real world' utility of miRNA patents: lessons learned from expressed sequence tags

Nature Biotechnology volume 29, pages 129133 (2011) | Download Citation

Strategies are needed for drafting miRNA patent applications, in light of the existing patent landscape and genomic patent strategies of the past decades.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature 391, 806–811 (1998).

  2. 2.

    & Nat. Rev. Genet. 5, 522–531 (2004).

  3. 3.

    , & Int. J. Biochem. Cell Biol. 42, 1252–1255 (2010).

  4. 4.

    et al. J. Neurosci. 30, 8245–8250 (2010).

  5. 5.

    & Biochem. Soc. Trans. 38, 1137–1143 (2010).

  6. 6.

    et al. PLoS ONE 5, e10480 (2010).

  7. 7.

    et al. PLoS ONE 5, e11243 (2010).

  8. 8.

    et al. Am. J. Pathol. 176, 1058–1064 (2010).

  9. 9.

    Biochim. Biophys. Acta 1805, 209–217 (2010).

  10. 10.

    & Cell Adh. Migr. 3, 425–432 (2009).

  11. 11.

    , , & Biochem. Biophys. Res. Commun. 393, 643–648 (2010).

  12. 12.

    et al. Cell Death Differ. 16, 1590–1598 (2009).

  13. 13.

    , & J. Cardiovasc. Transl. Res. 3, 212–218 (2010).

  14. 14.

    , & Mol. Endocrinol. 21, 1132–1147 (2007).

  15. 15.

    & Mol. Cell 20, 3–7 (2005).

  16. 16.

    et al. Science 308, 557–560 (2005).

  17. 17.

    , , & Proc. Natl. Acad. Sci. USA 103, 12481–12486 (2006).

  18. 18.

    , & Immunity 26, 133–137 (2007).

  19. 19.

    , , & Nat. Biotechnol. 23, 1227–1229 (2005).

  20. 20.

    US 11/747,409, Office Action dated February 13, 2009.

  21. 21.

    US 11/747,409, Reply to Office Action dated August 3, 2009; Cf. In re Fisher, 421 F.3d 1365, 1376 (Fed. Cir. 2005).

  22. 22.

    EP 02782801, Examiner's Report dated July 28, 2009.

  23. 23.

    Id.

  24. 24.

    <>

  25. 25.

    12/550,602, issued as US Patent No. 7,838,663 on November 23, 2010 (claims directed to miRNA-125a and 125b sequences); 12/550,586, issued as US Patent No. 7,838,661 on November 23, 2010 (claims directed to miRNA-124 sequences); 12/550, 704, issued as US Patent No. 7,838,664 on November 23, 2010 (claims directed to miRNA-142 sequences); 12/550,596, issued as US Patent No. 7,838,662 on November 23, 2010 (claims directed to miRNA-15a, 15b and 16 sequences); 12/550,579, issued as US Patent No. 7,838,660 on November 23, 2010 (claims directed to miRNA155 sequences).

  26. 26.

    35 USC §101.

  27. 27.

    Manual of Patent Examining Procedure §2107; “Utility Examination Guidelines,” Fed. Regist. 66, 1092–1099 (2001).

  28. 28.

    Manual of Patent Examining Procedure §2107.01; see also Fisher, 421 F.3d at 1376 (Fed. Cir. 2005).

  29. 29.

    Manual of Patent Examining Procedure §2107.01.

  30. 30.

    , et al. at n. 19; see also Overview of Comments in “Utility Examination Guidelines”. Fed. Regist. 66, 1092–1099 (2001).

  31. 31.

    J. Natl. Cancer Inst. 92, 96–97 (2000).

  32. 32.

    Manual of Patent Examining Procedure §2107.01(I)(A).

  33. 33.

    In re: Kirk, 376 F.2d 936 (CCPA 1967).

  34. 34.

    at n. 30.

  35. 35.

    Manual of Patent Examining Procedure §2107.01(I)(B).

  36. 36.

    Nelson v. Bowler, 626 F.2d 853 (CCPA 1980).

  37. 37.

    MPEP at n. 34.

  38. 38.

    Manual of Patent Examining Procedure §2107.02(III)(B).

  39. 39.

    Id.

  40. 40.

    Rasmusson v. SmithKline Beecham Corp., 75 USPQ 1297, 1300 (Fed. Cir. 2005), quoting Envirotech Corp. v. Al George, Inc., 221 USPQ 473 (Fed. Cir. 1984).

  41. 41.

    Rasmusson, at 1300.

  42. 42.

    421 F.3d 1365 (Fed. Cir. 2005).

  43. 43.

    d. at 1374.

  44. 44.

    Id.

  45. 45.

    421 F. 3d 1376.

  46. 46.

    A Bioinformatics Business Model and the Bold Strategy Behind It: The Case of Incyte Genomics, The American Conference Institute, 5th Advanced Forum on Biotech Patents (Sept. 2005). <>

  47. 47.

    Patenting Interfering RNA, SPE Art Unit 1635, USPTO (date unknown). <>

  48. 48.

    & in MicroRNA Protocols (ed. Ying, S.-Y.) 115–127 (Humana Press, 2006).

  49. 49.

    Rasmusson at n. 40.

  50. 50.

    et al. BMC Bioinformatics 10, 295–304 (2009).

  51. 51.

    , , , & Am. Univ. Law Rev. 51, 609–638 (2002).

  52. 52.

    35 USC §112 (2001).

  53. 53.

    et al. at n. 50.

  54. 54.

    Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563–64 (Fed. Cir. 1991).

  55. 55.

    US 10/909,125, Notice of Allowability dated October 22, 2009.

Download references

Author information

Affiliations

  1. Bonnie W. McLeod and Erich Veitenheimer are partners, Mark L. Hayman is an associate attorney and Angela L. Purcell and Joshua S. Marcus are patent agents at Cooley LLP, Washington, DC, USA.

    • Bonnie W McLeod
    • , Mark L Hayman
    • , Angela L Purcell
    • , Joshua S Marcus
    •  & Erich Veitenheimer

Authors

  1. Search for Bonnie W McLeod in:

  2. Search for Mark L Hayman in:

  3. Search for Angela L Purcell in:

  4. Search for Joshua S Marcus in:

  5. Search for Erich Veitenheimer in:

Competing interests

MiRagen, a company active in the microRNA space, is a Cooley patent prosecution client; and B.V.M. and E.V. previously represented the Carnegie Institution of Washington for the Andrew Fire/Craig Mello portfolio directed to RNAi.

Corresponding author

Correspondence to Bonnie W McLeod.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1765

Further reading Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing